12 results about "Immunogenic peptide" patented technology

This invention provides a specific detection method for *Daphnia magna* in nearshore marine aquatic ecosystem assessment. Based on obtaining the species-specific antigenic protein and key immunogenic peptides of *Daphnia magna*, a highly specific monoclonal antibody was successfully prepared and purified, and a colloidal gold side-flow chromatography rapid detection test strip was prepared using this antibody. The amino acid sequence of the antigenic protein is SEQ ID NO:1 or SEQ ID NO:2. This invention, by screening for the *Daphnia magna* species-specific antigen and its corresponding monoclonal antibody, combined with paired antibodies prepared from the full-length protein, and using them to develop a colloidal gold rapid immunoassay product, achieves for the first time high-throughput, rapid on-site screening of this species, significantly improving the efficiency and accuracy of marine ecological monitoring, ship ballast organism inspection, and aquaculture environmental assessment.

The present invention provides a T-cell receptor (TCR) that binds to an immunogenic peptide when the peptide is presented by the major histocompatibility complex (MHC).

The present invention provides a T cell receptor (TCR) that binds to immunogenic peptides when presented by major histocompatibility complexes (MHCs).

This disclosure relates to KRAS immunogenic peptides and their uses. According to this disclosure, the KRAS immunogenic peptides selectively bind to MHC class II in a preferential mode to selectively enhance the immunogenicity of specific immune cells capable of killing cancer cells, and thus can be advantageously used as superior cancer vaccines for the prevention and / or treatment of cancer by minimizing immune escape mechanisms of cancer cells.

An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.

The purpose of the present invention is to provide a new means for simply and efficiently encapsulating an immunogenic peptide in LNPs. Provided is a method for producing an immunogenic composition comprising LNPs having an immunogenic peptide encapsulated therein, the method comprising: a step for selecting a lipid component to be contained in LNPs in accordance with the charge of the immunogenic peptide in a buffer solution; and a step for mixing the immunogenic peptide dissolved in the buffer solution with the lipid component selected in the aforementioned step and the like to form the LNPs having the immunogenic peptide encapsulated therein.

The present invention provides a fusion protein of an extracellular vesicle surface marker protein or an extracellular vesicle transport signal peptide and a plurality of immunogenic peptides. An extracellular vesicle obtained from a cell expressing the fusion protein can be advantageously used in inducing antigen-specific immunity against each of the plurality of immunogenic peptides.

This invention provides an EBV immunogenic peptide, combinations thereof, and applications. The EBV immunogenic peptide comprises any of the amino acid sequences shown in SEQ ID NO:7-12 and SEQ ID NO:21. This invention also discloses a kit containing the EBV immunogenic peptide or combinations thereof, as well as other drugs for the prevention and / or treatment of EBV-related diseases, such as NK cells. This invention can achieve durable inhibition of EBV-positive nasopharyngeal carcinoma in humanized mouse models and enhance the infiltration and effector function of T cells and NK cells in the tumor microenvironment.